These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 872117)

  • 1. Immunological responsiveness in patients with bladder cancer.
    Fahey JL; Brosman S; Dorey F
    Cancer Res; 1977 Aug; 37(8 Pt 2):2875-8. PubMed ID: 872117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunocompetence of patients with transitional cell carcinoma as measured by dinitrochlorobenzene skin tests and in vitro lymphocyte function.
    Bean MA; Schellhammer PS; Herr HW; Pinsky CM; Whitmore WF
    Natl Cancer Inst Monogr; 1978 Dec; (49):111-4. PubMed ID: 155219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skin tests with soluble tumor membrane antigens in patients with transitional cell cancers.
    Hollinshead AC
    Natl Cancer Inst Monogr; 1978 Dec; (49):255-6. PubMed ID: 748779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adjuvant local BCG-immunotherapy in patients with urothel cancer of the bladder (author's transl)].
    Flamm J; Grof F
    Wien Med Wochenschr; 1981 Oct; 131(20):501-6. PubMed ID: 7314632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depression of the generation of cell-mediated cytotoxicity by macrophage-like suppressor cells in bladder carcinoma patients.
    Spina CA; Dorey F; Vescera C; Brosman S; Fahey JL
    Cancer Res; 1981 Nov; 41(11 Pt 1):4324-30. PubMed ID: 6458353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunologic indices of patients with transitional cell carcinoma of the urinary bladder].
    Bkhatta AD; Makhlin NV
    Urol Nefrol (Mosk); 1984; (2):67-70. PubMed ID: 6372193
    [No Abstract]   [Full Text] [Related]  

  • 7. [Changes in the mechanical integration of transitional epithelial cells and in the immune status of patients with bladder tumors].
    Bocharova OA; Serebriakova RV; Golubeva VA; Figurin KM; Bukharkin BV; Bodrova NB; Matveev BP; Baryshnikov AIu
    Urol Nefrol (Mosk); 1994; (3):27-30. PubMed ID: 8079407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of host immunocompetence in urologic cancer patients.
    Catalona WJ; Smolev JK; Harty JI
    J Urol; 1975 Dec; 114(6):922-6. PubMed ID: 1195475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukocyte migration inhibition in vitro in bladder carcinoma.
    Lavergne JA; Lamm DL; Radwin HM; Harrington JT
    Cancer Res; 1979 Jun; 39(6 Pt 1):1985-8. PubMed ID: 445398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation among host immunocompetence and tumor stage, tumor grade and vascular permeation in transitional carcinoma.
    Catalona WJ; Chretien PB
    J Urol; 1973 Nov; 110(5):526-8. PubMed ID: 4750895
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.
    Mizutani Y; Okada Y; Terachi T; Yoshida O
    J Urol; 1996 Mar; 155(3):888-92; discussion 892-4. PubMed ID: 8583600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancer.
    Fokdal L; Høyer M; von der Maase H
    Acta Oncol; 2004; 43(8):749-57. PubMed ID: 15764221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Results of long-term treatment of inoperable cancer of the bladder with cisplatin and concurrent irradiation: prognostic factors of local control and survival].
    Chauvet B; Félix-Faure C; Davin JL; Choquenet C; Alfonsi M; Reboul F
    Cancer Radiother; 1998 Apr; 2 Suppl 1():85s-91s. PubMed ID: 9749086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo skin test in carcinoma bladder.
    Gupta NP; Rajagopal V; Malaviya AN; Singh SM
    Indian J Cancer; 1984 Nov-1985 Jan; 21(5-6):163-5. PubMed ID: 6545227
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunologic evaluation of patients with cancer by delayed hypersensitivity reactions.
    Burdick JF; Wells SA; Herberman RB
    Surg Gynecol Obstet; 1975 Nov; 141(5):779-94. PubMed ID: 128144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M
    Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some immunological considerations relevant to the study of human bladder cancer.
    Bean MA
    Cancer Res; 1977 Aug; 37(8 Pt 2):2879-84. PubMed ID: 326394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological status of patients with bladder cancers (transitional cell tumours).
    Frantz P; Khoury S; Kuss R
    Prog Clin Biol Res; 1984; 162A():201-8. PubMed ID: 6385023
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunologic reduction of bladder cancer recurrence rate.
    Olsson CA; Chute R; Rao CN
    Trans Am Assoc Genitourin Surg; 1973; 65():66-72. PubMed ID: 4763514
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.